Leprosy remains an important health problem in a number of regions. Early detection of infection, followed by effective treatment, is critical to reduce disease progression. New sensitive and specific tools for early detection of infection will be a critical component of an effective leprosy elimination campaign. Diagnosis is made by recognizing clinical signs and symptoms, but few clinicians are able to confidently identify these. Simple tests to facilitate referral to leprosy experts are not widely available, and the correct diagnosis of leprosy is often delayed. In this report, we evaluate the performance of a new leprosy serological test (NDO-LID). As expected, the test readily detected clinically confirmed samples from patients with multibacillary (MB) leprosy, and the rate of positive results declined with bacterial burden. NDO-LID detected larger proportions of MB and paucibacillary (PB) leprosy than the alternative, the Standard Diagnostics leprosy test (87.0% versus 81.7% and 32.3% versus 6.5%, respectively), while also demonstrating improved specificity (97.4% versus 90.4%). Coupled with a new cell phone-based test reader platform (Smart Reader), the NDO-LID test provided consistent, objective test interpretation that could facilitate wider use in nonspecialized settings. In addition, results obtained from sera at the time of diagnosis, versus at the end of treatment, indicated that the quantifiable nature of this system can also be used to monitor treatment efficacy. Taken together, these data indicate that the NDO-LID/Smart Reader system can assist in the diagnosis and monitoring of MB leprosy and can detect a significant number of earlier-stage infections.
D
espite advances toward the elimination of leprosy over the last 2 decades, new case detection rates have stabilized over the last decade and leprosy remains an important health problem in many regions (1) . Like the number of registered cases, however, the number of clinicians who can reliably diagnose leprosy has waned, and delays in determining the correct diagnosis are common (2, 3) . Efforts to develop and improve surveillance and referral systems appear necessary to achieve the early detection required to ensure that prompt and appropriate treatment can be provided to limit disabilities. The development of simple and practical tools to facilitate diagnosis would appear prudent.
Currently, the diagnosis of leprosy is dependent on the appearance and recognition of clinical signs and symptoms. When skinsmear or pathology services are available, leprologists utilize the Ridley-Jopling scale to characterize five forms of the disease (4, 5) . In practice, however, most field programs lack such services, and the clinical system suggested by WHO to classify individual patients and to select their treatment regimen is used (6) . The WHO system uses skin lesions, bacterial positivity by skin smear, and the number of involved nerves to group leprosy patients into one of two simplified categories: multibacillary (MB) leprosy (patients are typically smear positive, have involvement of more than one nerve, or have more than 5 lesions) and paucibacillary (PB) leprosy (patients are smear negative, have no nerve involvement or involvement of one nerve, and have a maximum of 5 lesions). In many settings, particularly the poorest rural settings where access to experienced leprologists is limited or entirely absent, primary care providers cannot identify the signs of leprosy and patients are commonly misdiagnosed and mistreated (7) (8) (9) . With the delays in diagnosis of MB leprosy, transmission of Mycobacterium leprae from infected individuals to their contacts continues, and in many cases, irreversible nerve damage occurs before those infected are registered as patients (10) (11) (12) . Simple tools that can facilitate leprosy diagnosis could help to address this deficit.
While PB leprosy patients have absent bacterial indices (BI; a measure of the number of acid-fast bacilli in the dermis expressed in a logarithmic scale) and generally have low or absent anti-M. leprae antibody responses, MB leprosy patients do not control bacterial replication and demonstrate titers of anti-M. leprae antibodies that correlate with their bacterial burdens (4). Phenolic glycolipid I (PGL-I) is well recognized as a target of the antibody response of leprosy patients, with the magnitude of the response strongly correlating with BI (13) . To date, leprosy rapid diagnostic tests have comprised only PGL-I mimetics as the antigenic target (ML Flow test and Standard Diagnostics leprosy test [hereinafter called SD Leprosy], containing tri-or disaccharides NTP and NDO, respectively) (14-17). Using laboratory-based assays, our group and others have identified numerous native and recombinant proteins recognized by antibodies in MB leprosy patient serum (18) (19) (20) (21) (22) (23) (24) (25) . One example is the chimeric fusion protein leprosy IDRI diagnostic 1 (LID-1), an antigen specifically recognized by sera from leprosy patients from geographically and ethnically diverse populations, with a direct correlation between seroreactivity and BI (18, (26) (27) (28) . Complementary detection of antibodies against PGL-I or the components of LID-1 could lead to improved sensitivity within tests.
In conjunction with OrangeLife, Rio de Janeiro, we have created simple immunochromatographic lateral flow tests with the capacity to detect PGL-I-and LID-1-specific antibodies. In this report, we assess the performance of this new rapid diagnostic test against that of a previously available test using newly acquired and archived serum samples from clinically confirmed leprosy patients in Cebu, Philippines.
MATERIALS AND METHODS
Study site and participants. Blood samples were collected following local ethics committee approval from Cebu Skin Clinic attendees after they signed informed consent forms. Patients were fully characterized on the Ridley-Jopling scale by slit skin smear and biopsy (4) . Healthy household contacts (HHCs) of MB leprosy patients were enrolled as individuals at elevated risk of developing leprosy (29) . Individuals presenting with other skin conditions/diseases were also enrolled as endemic controls (ECs). Serum samples from a total of 208 newly diagnosed MB leprosy patients, 62 newly diagnosed PB leprosy patients, 51 healthy household contacts of MB leprosy patients, and 63 endemic controls were evaluated in distinct panels (Tables 1, 2 Rapid diagnostic tests. Sera were tested either within 2 h of collection or after thawing following storage at Ϫ20°C for up to 6 years. Two rapid diagnostic tests were evaluated: the SD Leprosy test was purchased from Standard Diagnostics (Yongin, South Korea), and NDO-LID was fabricated by OrangeLife (Rio de Janeiro, Brazil). Each is a simple immunochromatographic (lateral flow) test with the purpose of detecting circulating antibodies. The SD Leprosy test detects IgM antibodies to M. leprae-specific PGL-I through the use of NDO-bovine serum albumin (NDO-BSA; a synthetic mimetic of PGL-I conjugated to BSA), while NDO-LID detects IgM antibodies to PGL-I and IgG antibodies specific to LID-1 (the synthetic mimetic conjugated to the recombinant fusion protein product of the M. leprae genes ML0405 and ML2331) (18) . Evaluations with each rapid diagnostic test involved the addition of undiluted serum (10 l) and running buffer (2 to 3 drops; ϳ100 l) to a sample well, followed by readings of line development in the detection window after 10 min. Validation of the results required the visualization of a colored control line. A positive result was defined by the staining of both the control line and the test line; faint or no staining was considered a negative result. Visual readings were performed by a minimum of two independent readers.
Objective measurement of NDO-LID. NDO-LID tests have been adapted such that they can be read electronically by a Smart Reader, an Android-based smartphone rapid test reader platform mechanically attached to the existing camera unit (Fig. 1 ). This reader collected test images and objectively quantified the signal intensities of the control and test lines in each NDO-LID test. The calculation of Smart Reader cutoff values was based on the receiver operating curve, taking into account the visual results of the tests obtained with a panel of Brazilian MB leprosy patient samples and control samples. Assuming a sensitivity of 87%, as determined by visual readings, the Smart Reader cutoff was calculated as 9.99. For data analysis, the cutoff for positive results by the Smart Reader was therefore considered 10.0. Assuming this cutoff, the sensitivity of the test among the registration cohort of Brazilian MB leprosy patients was 87% (95% confidence interval [CI], 79.2 to 92.7%) and the specificity was 96.1% (95% CI, 91.7 to 98.6%), with an area under the curve (AUC) of 0.96 (standard deviation, 0.01; P Ͻ 0.0001) (30) .
Statistical analysis. Statistical significance was assessed using an unpaired t test for comparison between two groups. Results were considered statistically significant when P values of Ͻ0.05 were obtained.
RESULTS

Comparison of two rapid diagnostic tests for leprosy.
We analyzed sera using both the SD Leprosy test (based on the detection of IgM antibodies against the PGL-I mimetic NDO antigen) and the NDO-LID rapid diagnostic test (based on the detection of IgM antibodies against NDO and IgG antibodies against the LID-1 protein) to permit direct comparisons between these tests. In an initial study, subjective interpretation indicated that when developed with sera from MB leprosy patients, NDO-LID tests produced a significantly stronger band than that observed with SD Leprosy tests ( Fig. 2A) . This was true for both fresh and frozen samples (P values, 0.011 and 0.003, respectively). Sensitivity for MB leprosy patient samples in this initial study was found to be 93.8% (45 of 48 samples) with NDO-LID versus 77.1% (37 of 48) for SD Leprosy (Table 1) . While previous storage did not affect performance in the NDO-LID tests, the signal intensity of SD Leprosy tests was, surprisingly, lower when freshly prepared sera were added ( Fig. 2A) . These results were verified against another panel of sera ( Fig. 2B , P value of 0.02). PB leprosy patients have low or absent antibody responses and are not well recognized in rapid diagnostic tests containing only PGL-I mimetics (14, 16) . In agreement, when NDO-LID and SD Leprosy rapid diagnostic tests were developed with PB leprosy patient sera, only a subset of PB leprosy patient samples could be distinguished. A stronger signal was, however, observed with the NDO-LID tests than with the SD Leprosy tests, such that a greater proportion of PB leprosy patient samples were positive ( Fig. 2A, P value of Ͻ0.0001) ( Table 1 , 52.6% positive by NDO-LID versus 0.0% by SD Leprosy). Despite returning stronger results with patient samples, the NDO-LID tests were less likely to be positive than SD Leprosy tests when developed with sera from control individuals ( Fig. 2A and Table 1 , 0.0% positive by NDO-LID versus 25.0% by SD Leprosy). An independent follow-up study using only fresh sera confirmed that the NDO-LID test had a greater band intensity when developed with leprosy patient sera (Fig. 2B) and that a greater proportion of patients could be discriminated (Table 2) . Together, these data indicate that the NDO-LID test provides a greater differential of positive and negative results than the SD Leprosy test, with improved discrimination of leprosy patients from healthy individuals.
Objective and quantitative evaluation by NDO-LID. Visual interpretation of results is highly subjective and represents an important limitation when performed by personnel lacking expertise, limiting their scope of use. Results from any diagnostic test would ideally also be blinded from the clinical evaluation, but this is difficult to achieve in rural settings with limited resources. To address this deficit, a simple test reader (Smart Reader) can be used to permit objective scrutiny of data following the subjective evaluation of each NDO-LID. While readings on the control line were relatively consistent, a wide range of values were obtained when tests developed with sera from patients with MB leprosy were analyzed (Fig. 3A) . The Smart Reader identified an additional 1 and 5 samples as positive, respectively, increasing sensitivity to 95.8% in study A (46 of 48 samples) and 97.5% in study B (39 of 40). When signal intensities were compared, there was a highly significant correlation of readings (Spearman r, 0.967) (Fig.  3A) . Repetitive Smart Reader quantification of the same test, and repeat testing of the same sample, yielded highly consistent results (data not shown). In addition, although the manufacturer does not provide guidelines for reevaluation, only a minor but consistent drop in signal intensity was measured when values were reevaluated approximately 1 month later (Spearman r, 0.980) (Fig.  3B) . Thus, when coupled with a Smart Reader, NDO-LID tests provide rapid, consistent, robust, and objective quantification of seroreactivity.
Correlation of rapid diagnostic test results with BI. We then evaluated rapid diagnostic test performance across sera from patients with MB leprosy identified to have either high (Ͼ4.0), medium (2.0 to 3.9), or low (Ͻ2.0) BI at the time of clinical diagnosis. As expected, test bands were most intense for the high-BI patients and diminished as BI decreased (Fig. 4A) . While both rapid diagnostic tests performed well in detecting MB leprosy patients, the signal intensity was significantly greater in NDO-LID tests than in SD Leprosy tests. NDO-LID tests detected 20% of the PB leprosy serum samples in this testing round versus 10% detected by SD Leprosy tests. More importantly, while the SD Leprosy tests returned positive results for similar proportions of healthy household contacts and endemic controls (12.0 and 12.5%, respectively), the NDO-LID tests improved specificity (2.5% healthy household contacts were identified as being positive, and there were no positive results against endemic controls) ( Table 2 ). The subjective NDO-LID results were corroborated by Smart Reader (Fig. 4B) . Thus, the NDO-LID test can readily detect MB leprosy patients, and compared to the SD Leprosy test, it permits improved discrimination of PB leprosy patients from the general population.
Monitoring treatment by NDO-LID and Smart Reader. Smart Reader measurements could confer additional utility beyond initial detection and patient classification. To evaluate if the rapid diagnostic test/Smart Reader combination was sensitive enough to monitor treatment, we contrasted results generated using sera collected from patients at the time of diagnosis against sera collected at MDT completion. Overall, there was a reduced signal intensity in the after-treatment samples, with the decline most obvious in sera from patients that had the highest BI at intake ( Fig. 4B , P value of 0.003). In these high-BI MB leprosy patients, the mean reading of 46.3 at diagnosis declined to 27.7 after treatment, while in medium-BI MB leprosy patients, the de- Tests were developed, and examples of each scoring group that was subjectively assigned are shown. The NDO-LID tests have been adapted such that they can be read electronically by a Smart Reader application, an Androidbased cell phone rapid test reader platform mechanically attached to the existing camera unit.
cline was from 27.2 to 20.7, and in low-BI MB leprosy patients, it was from 10.2 to 6.1. These data suggest the utility of continued testing during, and even after, MDT.
DISCUSSION
Leprosy control programs are currently structured around the treatment of cases as they are reported. Case numbers are now relatively low in most regions, however, such that fewer clinicians have experience with the disease and only a limited number can confidently recognize the early signs of leprosy. Diagnosis is therefore commonly delayed, and the appearance of leprosy-associated disabilities may become more frequent (2, 3) . By lessening the reliance on the clinical exam and the recognition of symptoms, simple tools like the rapid diagnostic tests evaluated here could address this shortcoming. Tests could greatly aid general practitioners in their evaluation of suspected cases. This would appear particularly prudent in regions where a large proportion of patients present as MB leprosy cases, such as the Philippines (31) . Importantly, the ability to objectively read and quantify NDO-LID test results using a Smart Reader eliminates the need for prior training/experience in interpreting test results. This also provides an objective threshold and generates results that are consistent regardless of the many variables that could adversely affect test interpretation (different users, days, times of day, locations, etc.). This is of particular importance considering the possibility of individual bias in subjective reading of rapid tests in field conditions.
FIG 2
Improved performance of NDO-LID over SD Leprosy. In an initial study (A), stored (from MB leprosy patients only, n ϭ 38) or fresh (MB leprosy patients, n ϭ 10; PB leprosy patients, n ϭ 19; and EC, n ϭ 12) sera were tested by either the SD Leprosy or the NDO-LID rapid diagnostic test. The strength of the test band was then subjectively interpreted on a scale of 0 to 4 (negative to strong positive). In a follow-on study (B), fresh sera (MB leprosy patients, n ϭ 40; PB leprosy patients, n ϭ 13; HHC, n ϭ 26; and EC, n ϭ 11) were evaluated in the same manner, with the exception that the scoring scale had a maximum value of 3. Results from one interpreter are shown, and they were verified/corroborated by the additional interpreter. Strength of the NDO-LID test and control bands was then objectively measured using the Smart Reader (panel C indicates the objective measurement of the tests that were subjectively assessed in panel A, and panel D depicts the objective measurement of the tests subjectively assessed in panel B). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; and ****, P Ͻ 0.0001 between the indicated groups. Results in panels A and B are shown as means and standard errors of the means (SEM) for each group; horizontal bars in panels C and D indicate means.
The quantitative information could also be used to monitor individuals suspected of being infected with M. leprae over time or to expedite an informed referral to a leprosy expert.
The uptake of previous rapid tests for leprosy was restricted due to the relatively high proportion of seropositive results in the general population in regions of endemicity, despite the fact that the individuals with these results did not display clinical symptoms (15) . In any test, the threshold for a positive result is obviously critical to establish test performance, balancing sensitivity against specificity. Our previous results, obtained in the laboratory setting by enzyme-linked immunosorbent assays (ELISA), indicate that LID-1 provides an improved discrimination of leprosy patient samples from those of control subjects (18) . This would appear to continue through to the NDO-LID that contains a combination of NDO and LID-1. Our data not only demonstrate the utility of the NDO-LID but also strongly indicate an improved performance, in terms of both sensitivity and specificity, over that of the SD Leprosy rapid diagnostic test.
Consistent with WHO recommendations, Cebu Skin Clinic staff clinically examine contacts of MB leprosy patients at 6-month intervals over the course of 2 years following index case reporting (6) . While this system facilitates the earlier recognition of leprosy among these contacts, it is labor-intensive and timeconsuming, especially given Cebu's size. Additional practical and economic considerations (presence during visits, ensuring that work is not impacted, etc.) necessitate vigorous and sustained efforts to ensure that as many individuals can be observed as possible. Because the NDO-LID/Smart Reader is simple and rapid (10 to 20 tests can be conducted by one individual in 30 min), their integration could simplify and enhance this type of monitoring. The duration of any household visit could be markedly reduced, and evaluations could potentially be made at a much greater fre- (24, 27) . The levels detected in ELISA that have triggered such attention are readily detected in the NDO-LID test (30) . In addition, the robustness/stability of developed tests suggest that if tests perform equally well when using whole blood, they could be sent in advance to patients so that each of their household members could use them at a convenient time proximate to a surveillance visit. The long-term preservation of signal in the tests also suggests that they could even be returned to a central facility for quantitation. By simplifying the referral system, enhancing surveillance programs, or a combination of both, the use of an objective and quantifiable rapid diagnostic test could provide earlier detection and, through prompt treatment, a further reduction in leprosy-associated disabilities.
By lab-based ELISA, we previously identified reductions in patient antigen-specific antibody responses during treatment (24, 32) . These subtle changes can be captured by the NDO-LID/Smart Reader combination. In another study, we identified patients who were mistakenly undertreated or who had poor compliance with treatment (28) . We hypothesize that, in parallel with clinical examinations, thorough quantification of serological antibody responses by Smart Reader will allow us to capture nonresponse to treatment. Given that truncated treatment regimens are being proposed (33) (34) (35) (36) , projecting how a patient will respond to treatment without the need for invasive skin slits or biopsies would be an important and practical tool in trial design. Expanding evaluations into the treatment phase could ultimately provide objective guidelines for clinicians to identify high-risk groups requiring additional monitoring, permitting streamlining and prioritization within currently stretched control programs.
In summary, the highly quantifiable nature of the NDO-LID test/Smart Reader platform appears to have utility for detection and monitoring of MB leprosy. We believe it could enhance surveillance, facilitate referrals, and be an important tool in trials of new interventions and treatments.
